Fidelis Capital Partners LLC Sells 108 Shares of Cencora, Inc. (NYSE:COR)

Fidelis Capital Partners LLC reduced its holdings in shares of Cencora, Inc. (NYSE:COR) by 7.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,394 shares of the company’s stock after selling 108 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Cencora were worth $336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. bought a new position in Cencora during the 4th quarter valued at about $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Cencora during the first quarter valued at approximately $2,183,619,000. JPMorgan Chase & Co. bought a new position in Cencora during the first quarter valued at approximately $1,199,695,000. Boston Partners purchased a new stake in Cencora in the first quarter worth approximately $1,001,269,000. Finally, Capital Research Global Investors bought a new stake in Cencora in the 1st quarter worth approximately $650,424,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Wells Fargo & Company increased their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday. JPMorgan Chase & Co. boosted their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Bank of America reiterated a “neutral” rating and issued a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Leerink Partners restated an “outperform” rating and set a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $256.67.

Cencora Price Performance

NYSE COR opened at $228.36 on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. Cencora, Inc. has a 12 month low of $178.21 and a 12 month high of $247.66. The stock has a market cap of $45.55 billion, a price-to-earnings ratio of 24.98, a PEG ratio of 1.55 and a beta of 0.44. The company’s 50 day moving average is $234.97 and its two-hundred day moving average is $233.04.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating the consensus estimate of $3.18 by $0.16. The firm had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company’s revenue was up 10.8% on a year-over-year basis. During the same period last year, the firm earned $2.92 EPS. As a group, research analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is 22.32%.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,450,399 shares of company stock worth $1,070,392,799. 15.80% of the stock is owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.